Jazz Pharmaceuticals plc(JAZZ)Earnings, Financials & Key RatiosJazz Pharmaceuticals plc (JAZZ) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has successfully reduced its debt-to-equity ratio to 0.24, the reliance on inorganic growth and the potential for future patent cliffs suggest that the current forward P/E of 9.07 may already reflect these operational risks.
Jazz Pharmaceuticals plc (JAZZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Jazz Pharmaceuticals plc (JAZZ) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $6.34vs $4.64+36.6% | $1.1Bvs $979M+9.2% |
| Q1 2026 | Feb 24, 2026 | $6.64vs $6.52+1.8% | $1.2Bvs $1.2B+2.8% |
| Q4 2025 | Nov 5, 2025 | $8.13vs $5.95+36.6% | $1.1Bvs $1.1B+1.3% |
| Q3 2025 | Aug 5, 2025 | $8.25vs $6.12-34.8% | $1.0Bvs $1.0B-0.1% |
Recent stock market news and headlines for Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals is testing a bull flag breakout following a long-term base advance, with confirmation needed above key swing resistance to validate continuation toward new highs.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zepzelca's failed trial doesn't derail Jazz's growth strategy. First-line adoption is becoming Zepzelca's biggest opportunity.
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
Key metrics vs top competitors for Jazz Pharmaceuticals plc (JAZZ)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $237.51 | $14.9B | -40.67 | 4.88% | -8.35% | -8.47% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $25.03 | $984.56M | 156.44 | 3.63% | 1.27% | 1.31% | — | |
| $21.90 | $1.62B | 6.64 | 18.52% | 118.91% | 47.59% | — | |
| $24.63 | $1.15B | -16.87 | 1.95% | -9.69% | -8.91% | — | |
| $10.31 | $1.43B | -1.00 | -2.75% | -43.5% | -50.65% | — |
Jazz Pharmaceuticals plc (JAZZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Jazz Pharmaceuticals plc (JAZZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Feb 24, 2026·SEC
Jan 12, 2026·SEC
Get notified when JAZZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Jazz Pharmaceuticals plc (JAZZ) stock FAQ — growth, dividends, profitability & financials explained
Jazz Pharmaceuticals plc (JAZZ) reported $4.44B in revenue for fiscal year 2025. This represents a 20601% increase from $21.4M in 2005.
Jazz Pharmaceuticals plc (JAZZ) grew revenue by 4.9% over the past year. Growth has been modest.
Yes, Jazz Pharmaceuticals plc (JAZZ) is profitable, generating $29.5M in net income for fiscal year 2025 (-8.3% net margin).
Jazz Pharmaceuticals plc (JAZZ) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.
Jazz Pharmaceuticals plc (JAZZ) generated $1.25B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
